Company attributes
Industry
Location
Email Address
privacy@antengene.com
Place of Incorporation
Investors
Founded Date
2016
Total Funding Amount (USD)
337,000,000
Latest Funding Round Date
July 20, 2020
Stock Symbol
6996.HK
Exchange
Latest Funding Type
Country
Headquarters
Other attributes
Company Operating Status
Active
Latest Funding Round Amount (USD)
97,000,000
Antengene is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. Antengene has established a pipeline of 12 drug assets focused on oncology, including two late-stage clinical assets, four early-stage clinical assets. In addition, leveraging R&D capabilities, Antengene are internally developing six pre-clinical stage assets, which focus on novel targets or MoAs and hence have potential to address significant unmet medical needs. More importantly, these assets target the key oncogenic pathways and are highly synergistic to our pipeline assets.
Timeline
No Timeline data yet.
Funding Rounds
Products
Acquisitions
SBIR/STTR Awards
Patents
Further Resources
No Further Resources data yet.